Strides Pharma Science · NSE: STAR · BSE: 532531

Q4 FY22 results · Jan–Mar 2022

Strides Pharma Science reported revenue from operations of ₹866.02 crore (down 4.7% from Q4 FY21) and net profit of ₹28.96 crore (down 33.8% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	866.02	908.49	−4.7%	794.39	+9.0%
Other income	86.06	13.05	+559.5%	10.19	+744.6%
Total income	952.08	921.54	+3.3%	804.58	+18.3%
Profit before share of associates & JVs and tax	(58.88)	75.89	Turned loss	(106.86)	Loss narrowed
Share of profit/(loss) of associates & JVs	(43.64)	(19.82)		(24.27)
Net profit for the period	28.96	43.74	−33.8%	(126.66)	Turned profit
Attributable to shareholders of the company	29.22	46.09	−36.6%	(121.67)	Turned profit
EPS, basic (₹)	3.25	5.14	−36.8%	(13.55)	Turned profit
Net margin (%)	3.3	4.8		-15.9

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	455.66	633.60	−28.1%	439.56	+3.7%
Other income	84.83	23.31	+264.0%	7.50	11x
Total income	540.49	656.90	−17.7%	447.06	+20.9%
Profit before tax	56.71	68.69	−17.5%	(31.69)	Turned profit
Net profit for the period	200.50	48.08	+317.1%	(17.60)	Turned profit
EPS, basic (₹)	22.33	5.36	+316.6%	(1.96)	Turned profit
Net margin (%)	44.0	7.6		-4.0

Consolidated

Filed with BSE: 25 May 2022, 16:03 IST
Board meeting: 24 May 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 25 May 2022, 16:03 IST
Board meeting: 24 May 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Audited
Source: XBRL filing on BSE